UroGen Pharma (URGN) director converts 2,000 RSUs into ordinary shares, holds 6,000

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

UroGen Pharma director James A. Robinson Jr. exercised restricted stock units into ordinary shares, increasing his direct share ownership. He acquired 2,000 ordinary shares through an RSU conversion and now directly holds 6,000 ordinary shares, with 2,000 RSUs remaining outstanding as a separate derivative holding.

Insider Trade Summary

2,000 shares exercised/converted

Mixed 2 txns

Insider Robinson James A. Jr.

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	2,000	$0.00	--
Exercise	ordinary shares	2,000	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 2,000 shares (Direct, null); ordinary shares — 6,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs exercised: 2,000 units Ordinary shares acquired: 2,000 shares Direct ordinary share holdings: 6,000 shares +2 more

5 metrics

RSUs exercised 2,000 units Converted into ordinary shares on 2026-05-26

Ordinary shares acquired 2,000 shares From RSU exercise on 2026-05-26

Direct ordinary share holdings 6,000 shares Total held after transactions

RSUs remaining 2,000 units Derivative holdings after exercise

Exercise price per RSU $0.00 RSU conversion terms

Key Terms

Restricted Stock Unit, ordinary shares, derivative security, Form 4

4 terms

Restricted Stock Unit financial

"The Form 4 involves ordinary shares and Restricted Stock Units (RSUs)."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

ordinary shares financial

"He converted 2,000 RSUs into 2,000 ordinary shares, increasing his direct equity stake"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

derivative security financial

"The transactions reflect derivative exercises, not open-market trades."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 regulatory

"What insider transaction did UroGen Pharma (URGN) disclose for James A. Robinson Jr.?"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/27/2026 - 08:04 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson James A. Jr.

(Last)

(First)

(Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON

NEW JERSEY

08540

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ordinary shares	05/26/2026		M		2,000	A	⁽¹⁾	6,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	05/26/2026		M			2,000	⁽¹⁾	⁽¹⁾	Ordinary Shares	2,000	$0	2,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

	/s/ Jason D. Smith, Attorney-in-Fact	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did UroGen Pharma (URGN) disclose for James A. Robinson Jr.?

UroGen Pharma reported that director James A. Robinson Jr. exercised restricted stock units into ordinary shares. He converted 2,000 RSUs into 2,000 ordinary shares, increasing his direct equity stake while retaining additional RSUs for future potential share delivery.

How many UroGen Pharma (URGN) shares does James A. Robinson Jr. hold after this Form 4?

After the reported transactions, James A. Robinson Jr. directly holds 6,000 ordinary shares of UroGen Pharma. This reflects the addition of 2,000 shares acquired from RSU conversion, alongside his prior holdings already reported in earlier filings.

What type of securities did the UroGen Pharma (URGN) Form 4 involve?

The Form 4 involves ordinary shares and Restricted Stock Units (RSUs). RSUs are derivative awards that convert into ordinary shares, with each RSU representing a contingent right to receive one ordinary share when vesting or settlement conditions are met.

Was there any open-market buying or selling of UroGen Pharma (URGN) stock in this Form 4?

The transactions reflect derivative exercises, not open-market trades. James A. Robinson Jr. acquired 2,000 ordinary shares by converting RSUs, with no shares reported as sold or disposed of on the open market in this filing.

How many Restricted Stock Units does James A. Robinson Jr. retain at UroGen Pharma (URGN)?

Following the transactions, James A. Robinson Jr. has 2,000 Restricted Stock Units outstanding. Each RSU represents a contingent right to receive one ordinary share of UroGen Pharma upon satisfaction of relevant vesting or settlement terms.